Table 1.

Demographic and baseline characteristics of RTR-PD subpopulation

Recipient CharacteristicBelatacept MI (n = 114)Belatacept LI (n = 97)CsA (n = 125)
Mean age, years (SD)53 (14.3)53 (11.9)53 (13.3)
Gender, n (%)
    male82 (71.9)72 (74.2)88 (70.4)
    female32 (28.1)25 (25.8)37 (29.6)
Race, n (%)
    Caucasian70 (61.4)59 (60.8)80 (64.0)
    African American15 (13.2)19 (19.6)22 (17.6)
    Native American/Alaskan Native1 (0.9)1 (1.0)0 (0.0)
    Asian15 (13.2)12 (12.4)9 (7.2)
    other13 (11.4)6 (6.2)14 (11.2)
Geographic region, n (%)
    North America63 (55.3)49 (50.5)57 (45.6)
    South America14 (12.3)11 (11.3)22 (17.6)
    Europe26 (22.8)25 (25.8)38 (30.4)
    Asia/Pacific10 (8.8)10 (10.3)7 (5.6)
    Africa1 (0.9)2 (2.1)1 (0.8)
Reported cause of ESRD, n (%)
    glomerular disease9 (7.9)19 (19.6)18 (14.4)
    diabetes57 (50.0)41 (42.3)62 (49.6)
    polycystic kidneys9 (7.9)9 (9.3)8 (6.4)
    hypertension (primary and secondary)19 (16.7)12 (12.4)17 (13.6)
    congenital, familial, metabolic disorders2 (1.8)0 (0.0)3 (2.4)
    tubular and interstitial diseases4 (3.5)2 (2.1)5 (4.0)
    retransplant/graft failure0 (0.0)2 (2.1)0 (0)
    other14 (12.3)12 (12.4)12 (9.6)
Categorized PRA, n (%)
    <20%106 (93.0)87 (89.7)117 (93.6)
    ≥20%7 (6.1)9 (9.3)4 (3.2)
    missing1 (0.9)1 (1.0)4 (3.2)
  • CsA, cyclosporine; LI, less intensive; MI, more intensive; PRA, panel reactive antibody; RTR-PD, renal transplant recipients with preexisting diabetes.